Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody

This publication has 9 references indexed in Scilit:

• Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants
  The Pediatric Infectious Disease Journal, 2000
• Reduction of Respiratory Syncytial Virus (RSV) in Tracheal Aspirates in Intubated Infants by Use of Humanized Monoclonal Antibody to RSV F Protein
  The Journal of Infectious Diseases, 1998
• Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants
  Pediatrics, 1998
• Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus
  The Journal of Infectious Diseases, 1997
• Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis
  Pediatrics, 1997
• Comparison of Antibody Concentrations and Protective Activity of Respiratory Syncytial Virus Immune Globulin and Conventional Immune Globulin
  The Journal of Infectious Diseases, 1994
• Immunoprophylaxis and Immunotherapy of Respiratory Syncytial Virus–Infected Mice with Respiratory Syncytial Virus–Specific Immune Serum
  Pediatric Research, 1993
• Protective Activity of a Human Respiratory Syncytial Virus Immune Globulin Prepared from Donors Screened by Microneutralization Assay
  The Journal of Infectious Diseases, 1992
• Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat
  Virus Research, 1985